Author: Creative Medical Technology Holdings, Inc.

Posted Date:

April 28, 2026

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

Creative Medical Technology Holdings, Inc.

April 28, 2026
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline

Creative Medical Technology Holdings, Inc.

February 11, 2026